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ABSTRACT
Introduction Herpes simplex virus (HSV) encephalitis is 
a rare severe form of brain inflammation that commonly 
leaves survivors and their families with devastating 
long- term consequences. The virus particularly targets 
the temporal lobe of the brain causing debilitating 
problems in memory, especially verbal memory. It is 
postulated that immunomodulation with the corticosteroid, 
dexamethasone, could improve outcomes by reducing 
brain swelling. However, there are concerns (so far not 
observed) that such immunosuppression might facilitate 
increased viral replication with resultant worsening of 
disease. A previous trail closed early because of slow 
recruitment.
Method DexEnceph is a pragmatic multicentre, 
randomised, controlled, open- label, observer- blind trial 
to determine whether adults with HSV encephalitis who 
receive dexamethasone alongside standard antiviral 
treatment with aciclovir for have improved clinical 
outcomes compared with those who receive standard 
treatment alone. Overall, 90 patients with HSV encephalitis 
are being recruited from a target of 45 recruiting sites; 
patients are randomised 1:1 to the dexamethasone or 
control arms of the study. The primary outcome measured 
is verbal memory as assessed by the Weschler Memory 
Scale fourth edition Auditory Memory Index at 26 weeks 
after randomisation. Secondary outcomes are measured 
up to 72 weeks include additional neuropsychological, 
clinical and functional outcomes as well as comparison of 
neuroimaging findings. Patient safety monitoring occurs 
throughout and includes the detection of HSV DNA in 
cerebrospinal fluid 2 weeks after randomisation, which is 
indicative of ongoing viral replication. Innovative methods 
are being used to ensure recrutiment targets are met for 
this rare disease.
Discussion DexEnceph aims to be the first completed 
randomised controlled trial of corticosteroid therapy in HSV 
encephalitis. The results will provide evidence for future 
practice in managing adults with the condition and has the 
potential to improve outcomes .
Ethics and dissemination The trial has ethical approval 
from the UK National Research Ethics Committee 
(Liverpool Central, REF: 15/NW/0545, 10 August 2015). 
Protocol V.2.1, July 2019. The results will be published and 
presented as soon as possible on completion.
Trial registration numbers ISRCTN11774734, EUDRACT 
2015-001609-16.
INTRODUCTION
Herpes simplex virus infection (HSV) is 
the most commonly identified viral cause 
of encephalitis, inflammation and swelling 
of the brain caused by a virus or the body’s 
immune system, in the UK as in most western 
industrialised nations.1–4 The incidence has 
been estimated at 1 in 250 000–500 000,2 with 
evidence it may be higher.4 Although a rare 
disease, HSV encephalitis has a dispropor-
tionately large impact due to its devastating 
long term neuro- psychological sequelae . 
These can have a marked impact on the 
quality of life of the patient and their family 
and high health economic and social costs.5 6
Strengths and limitations of this study
 ► DexEnceph will be the first completed randomised 
controlled trial of corticosteroids in herpes simplex 
virus encephalitis, examining the utility and safety.
 ► DexEnceph’s primary end point is verbal memory 
score recorded at 26 weeks after randomisation, 
this represents the most important neuropsycholog-
ical damage
 ► The recruitment target is informed by the recent 
Enceph- UK programme grant of encephalitis in the 
UK; the trial is currently open and has recruited 82 
patients of a target 90.
 ► Innovative methods for engaging with recruitment 
sites have been key to ensuring the success of the 
study.
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Since the introduction of the antiviral drug aciclovir in 
the 1970s, the mortality of HSV encephalitis has reduced 
from around 70% to 5.5%–12%.7–9 However, survivors 
are commonly left with neurological impairment; less 
than 20% of patients are able to return to work and 48% 
are classed as moderate to severely disabled.10 Even when 
obvious disabilities have not occurred, families often 
report personality changes—the person they take home 
from hospital is simply not the same as the one before the 
illness.6 11
HSV encephalitis can cause a broad range of cognitive 
impairments, but impaired memory, especially verbal 
memory, is the most common and likely relates to the viral 
predilection for the temporal lobe of the brain.12 13 The 
verbal memory deficits manifest as difficulties remem-
bering names of objects and people, as well as listening 
to and recalling spoken information for example in 
conversations.14 15 In addition to memory problems, diffi-
culties in processing speed, concentration, language and 
executive function are also common among survivors of 
HSV encephalitis, along with fatigue, poor concentration, 
anxiety and depression.7 16 17
The pathogenic mechanisms in HSV encephalitis are 
not fully understood. The evidence suggests that in addi-
tion to direct viral pathogenesis, inflammation of the 
brain in response to the virus is a key component of the 
disease process.18–21 This is supported by the observa-
tion that in the cerebrospinal fluid (CSF), higher levels 
of proinflammatory chemokines, especially monocyte 
chemotactic protein-1, interferon γ and interleukin 6 
(IL-6) are associated with a worse prognosis.22 23 Poor 
prognosis is also associated with the extent of inflamma-
tion seen on neuroimaging,24 and the degree of temporal 
lobe swelling is correlated with the severity of verbal 
memory impairment.25 Relapse occurs in about approx-
imately 10% of HSV encephalitis patients, and is some-
times associated with the development of anti- N- Methyl- D 
Aspartic acid (NMDA) antibodies.26
Control of the inflammation in HSV encephalitis may 
improve outcome, as shown in mouse models of the 
disease.27–29 Before the availability of aciclovir, corticoste-
roids were sometimes used as a treatment in humans with 
HSV encephalitis,30 31 and more recently both cerebral 
oedema on imaging and CSF IL-6 levels were shown to 
be reduced in patients given corticosteroids.23 However, 
because corticosteroids cause immunosuppression, which 
in theory facilitates increased viral replication, their role 
is uncertain.32
In other brain infections, including bacterial menin-
gitis and tuberculous meningitis the benefit of corticoste-
roids has been demonstrated in large clinical trials.33 For 
HSV encephalitis the potential benefit of using corticoste-
roid as an adjunct to aciclovir therapy has been suggested 
from small case series and retrospective comparisons, 
but there has been no prospective randomised study 
reported.34–39 One study, the German trial of Aciclovir 
and Corticosteroids in Herpes simplex virus Encephalitis 
(the GACHE trial) was stopped early because of poor 
recruitment rates.40 However, there is clearly a need for 
a study to answer this question. The DexEnceph Study, 
a randomised controlled trial of dexamethasone in HSV 
encephalitis, aims to achieve this.
Trial design
DexEnceph is a pragmatic, multicentre, randomised, 
controlled, observer- blind trial to determine whether the 
addition of dexamethasone to standard aciclovir treat-
ment improves clinical outcomes (in particular verbal 
memory score) for adults with HSV encephalitis. Addi-
tionally, neuroimaging and biomarkers are assessed along 
with detection of HSV in the CSF at 2 weeks after rando-
misation to monitor for difference in viral replication 
between the two groups.
Primary objective
To determine whether a short course of intravenous dexa-
methasone, in addition to standard care, improves verbal 
memory score in adults with HSV encephalitis at 26 weeks 
after treatment compared with standard care alone.
Secondary objectives
Secondary objectives include the following:
To determine whether dexamethasone therapy has an 
effect on other neuropsychological, cognitive, clinical, 
disability and functional outcomes in HSV encephalitis.
To assess the effect of dexamethasone therapy on brain 
swelling examined by neuroimaging .
To determine whether dexamethasone therapy affects 
clearance of HSV from the CSF, the emergence of NMDA 
receptor antibody or causes any changes in transcrip-
tomic and proteomic profiling in the CSF and blood.
A more comprehensive list of measures is detailed in 
the outcomes section.
METHODS AND ANALYSIS
DexEnceph is an observer- blind, open- label, prospective, 
randomised, controlled trial of dexamethasone at 10 mg 
four times daily for 4 days, versus no dexamethasone, in 
adults with HSV encephalitis.
Research setting
The trial is being conducted in up to 45 National Health 
Service (NHS) trusts, with a recruitment target of 0–2 
patients per site per year. A full list of sites involved in 
DexEnceph can be obtained from www. dexenceph. org. 
uk. The trail uses Standard Protocol Items: Recommen-
dations for Interventional Trials reporting guidelines41 
(online supplemental file 1).
Eligibility criteria
Inclusion criteria
Enrolled patients fulfil all of the following criteria:
1. Suspected encephalitis defined as: new- onset seizure or 
new focal neurological signs or alteration in conscious-
ness, cognition, personality or behaviour. Personality/
behavioural change includes agitation, psychosis, 
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somnolence, insomnia, catatonia, mood lability, and 
altered sleep pattern.
2. A positive HSV DNA PCR result from CSF, reported 
not more than 7 days prior to randomisation.
3. Receiving intravenous aciclovir administered as 10 mg/
kg three times daily or at a reduced dose if clinically 
indicated.
4. Age≥16 years.
5. Written informed consent given by the patient or their 
legal representative42
Exclusion criteria
Patients are excluded if they have any of the following:
1. Have received oral or injectable corticosteroid therapy 
in the 30 days prior to the day of entry to the study. 
This does not apply to topical/ inhaled corticosteroids. 
(Patients who have received oral or injectable cortico-
steroid therapy AFTER their admission to hospital will 
not be excluded from the study if they consent to trial 
participation).
2. History of hypersensitivity to corticosteroids.
3. Immunosuppression secondary to:
a. Known HIV infection and CD4 white cell count un-
der 200/mm3.
b. Currently taking biological therapy or other immu-
nosuppressive agents (eg, azathioprine, methotrex-
ate, ciclosporin)
c. Previous solid organ transplant and currently on im-
munosuppression.
d. Previous bone marrow transplant.
e. Currently undergoing a course of chemotherapy or 
radiotherapy.
f. Known primary immunodeficiency syndrome.
g. Known current haematological malignancy.
4. Pre- existing indwelling ventricular devices.
5. Peptic ulcer disease in the last 6 months, defined as a 
peptic ulcer seen at endoscopy or an upper gastroin-
testinal bleed causing a ≥2 unit haemoglobin drop, in 
the last 6 months.
6. Antiretroviral regimen containing rilpivirine as current 
treatment (levels of rilpivirne are known to significant-
ly decrease in coadministration with dexamethasone, a 
switch to a suitable alternative can facilitate trial entry).
Intervention
Participants are randomised in a 1:1 ratio to dexametha-
sone four times daily for 4 days alongside standard care, 
or standard care alone (figure 1). Standard care includes 
intravenous aciclovir for a minimum of 14 days based on 
an ideal body weight at 10 mg/kg every 8 hours, unless 
dose adjustment to account for renal impairment is 
necessary. Participating clinicians remain free to modify 
or discontinue the dexamethasone administration or to 
give alternative treatments at any stage, if this is judged to 
be in the best interest of the patient.
Participants assigned dexamethasone receive 10 mg 
equivalent of ordinary ward stock, prescribed by an autho-
rised member of the local study team, given intravenously 
four times daily for 4 days (16 doses in total) starting 
within 24 hours of randomisation.
The University of Liverpool employs a clinical trials 
unit to be responsible for screening, and monitoring data 
collection, quality and completeness. As there is a low 
number of participants to be recruited, the trials unit are 
able to liaise regularly with each site following randomi-
sation to ensure all follow- up data are collected. Primary 
outcome is recorded by a centrally employed roving 
neuropsychologist, who collects the neuropsychological 
outcomes at 26 and 72 weeks.
Outcome measures
Primary outcome
Verbal memory score, determined by the Wechsler 
Memory Scale fourth edition (WMS- IV) Auditory Memory 
Index, at 26 weeks after randomisation. Patients that die 
will be allocated the lowest possible WMS- IV score.
Secondary outcomes
Other neuropsychological outcome measures (at 26 
weeks and 78 weeks after randomisation):
 ► Verbal memory score, determined by the WMS- 
IV, Auditory Memory Index, at 78 weeks after 
randomisation.
 ► Visual, Immediate and Delayed Memory by Indexes of 
the WMS- IV, processing speed and working memory 
Figure 1 Schematic design of DexEnceph randomised 
controlled trial.
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subscales from the Wechsler Adult Intelligence Scale 
Fourth Edition.
 ► Higher executive function using the Trail Making 
Test.
 ► Anxiety and Depression symptom levels by the Beck 
Depression Inventory and Beck Anxiety Inventory.
 ► Subjective cognitive complaints using the Perceived 
Deficits Questionnaire.
Cognitive Outcome Measures (at discharge or 30 days if 
still in hospital, 26 weeks and 78 weeks).
 ► Addenbrooke’s Cognitive Assessment III.
Clinical Outcomes
 ► Incidence of epilepsy.
 ► Time to hospital discharge.
 ► Requirement of high- dependency unit or intensive 
care unit admission up to 30 days after randomisation.
 ► Time taken to be free of ventilatory support for 14 
days (if any).
 ► Time to reach maximum recorded Glasgow Coma 
Scale score.
 ► Survival.
Disability and functional outcomes (at discharge or 30 
days if still in hospital, 26 weeks and 78 weeks):
 ► Modified Rankin Score, Barthel Index, Liver-
pool Outcome Score and Glasgow Outcome Scale 
Extended.
Imaging Outcomes: Change from Baseline at 2 weeks, 
26 weeks and 78 weeks
 ► Temporal lobe volume (as percentage of intracranial 
volume).
 ► Whole brain volume (as percentage of intracranial 
volume).
 ► Volume of affected region as seen on fluid- attenuated 
inversion recovery image (as percentage of intracra-
nial volume).
 ► Volume of affected region as seen on diffusion- 
weighted image (as percentage of intracranial 
volume).
Biomarker outcomes
 ► Transcriptomic and proteomic profiling on blood 
at convalescence (2 weeks and 26 weeks), compared 
with acute baselines, and on CSF at 2 weeks compared 
with acute baseline.
 ► Anti- NMDA receptor antibody testing at 26 weeks.
Safety outcomes
 ► Proportion of patients with detectable HSV in CSF by 
PCR at 2 weeks.
Health Status and Quality of Life (at 26 and 78 weeks):
 ► Measured by the EuroQoL-5 Dimension-5 Level 
quality of life scale and 36 item Short- Form Survey 
self- completed questionnaires.
Screening
The majority of potential patients are identified by 
the local research team through identifying patients 
with a relevant clinical presentation suspicious of HSV 
encephalitis and/or detection of HSV in a CSF sample. 
A screening log is completed for all potential patients. A 
strong link with the local laboratory is essential as a key 
factor in ensuring eligible patients are not missed by the 
investigative team. Investigators for the local research 
team include neurologists, infectious disease clinicians, 
acute medics, microbiologist and virologists.
Because this is a rare disease, most centres will only see 
1-2 potential patients a year. Extra measures have there-
fore been taken to try and maximise recruitment. On 
identifying a suitable patient, sites are able to contact the 
trial management team for intensive support via a dedi-
cated telephone hotline, email, or an app. Short videos 
which explain the trial to patients, families and to health-
care workers also support recruitment. Every month, the 
trial management group monitor the screening reports 
of each site for the previous 3 months, to ensure they 
are actively looking for patients. Lower than expected 
screening is followed up by the central study team making 
contact with the study site to review their screening meth-
odology and offer support.
Randomisation
Participants are randomised using a 24- hour secure web- 
based programme, which is centrally controlled by the 
clinical trials research centre. Designated members of 
the trial team at the site (detailed on the delegation of 
responsibilities log) are provided with a unique username 
and password which is required to access the web- based 
randomisation system. In the event of system failure, the 
patient can be randomised centrally electronically or 
through secure envelopes. Each participant is allocated 
a unique study number (randomisation number), the 
primary identifier for all the participants in this study.
The neuropsychologist collecting the primary outcome 
and other outcome assessors such as radiologists and the 
lead investigators are blinded to randomisation during 
the trial. Trial participants and local site study teams, as 
well as the trial manager and trial data manager at the 
clinical trials unit are aware of what treatments have been 
allocated. The independent data safety and monitoring 
committee (IDSMC) and statisticians have access to 
unblinded data grouped by intervention throughout the 
trial and make recommendations to the trial’s steering 
committee who would only become unblinded in the 
event of a serious event.
Participant timeline
The time schedule for enrolment, interventions and 
assessments is given in table 1.
Statistical considerations
Sample size
The primary outcome variable is verbal memory, assessed 
as part of WMS- IV. In one published series of adults who 
survived HSV encephalitis, 19 of 22 had memory impair-
ment evident at follow- up, with verbal memory being most 
severely affected.12 In that study the mean (SD) verbal 
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memory score was 88.9 (18.9) compared with the popula-
tion mean (SD) of 100.15 This score can only be assessed 
in survivors, we estimate approximately 10% of patients 
in the trial will die before assessment of the primary 
outcome.8 43 44 In instances where the death is judged to 
be associated with encephalitis the verbal memory score 
is recorded as 40, (the lowest possible value which would 
be obtained even where a patient recorded no recall of 
any of the items administered in the memory subtests). 
Where the cause of death is thought to be independent of 
having encephalitis, those patients will be recorded as lost 
to follow- up. Similarly, for patients who are too unwell, 
due to encephalitis, to undergo the assessment, the score 
is recorded as 40. Decisions as to whether the reasons for 
death or non- completion of the measures were due to 
encephalitis will be made by an independent committee 
blinded to dexamethasone allocation. Adjusting the esti-
mate of mean and SD from survivors, to include the 10% 
of patients that die having the lowest possible value of 40, 
gives a total population mean of 84.8, with a SD of 23.1. 
A final sample size of 36 participants per group allows us 
to detect a clinically meaningful difference of 15.5 on 
the verbal memory score with 80% power, at a two- sided 
significance level of 0.05. Allowing for up to 20% dropout 
gives an initial target sample size of 45 participants per 
group, for a total of 90.
Statistical analysis
For the primary outcome, participants are included in the 
analysis based on the intention- to- treat principle. Verbal 
Table 1 Time scale for patients randomised in the DexEnceph study
Procedures
Inntervention and follow- up schedule
Screening Baseline 2 weeks









Signed consent form X* X†
Assessment of eligibility 
criteria
X X†
Review of medical 
history
  X†
Review of concomitant 
medications
  X† X X X X X
Physical exam   X X
Study intervention   X
Clinical data collection   X X X X
MRI scan   X‡ X X X
Research blood testing   X X X
Lumbar puncture   X§ X
Disability and functional 
outcomes
    X X X
Glasgow Coma Scale   X¶† X¶ X¶ X X
Addenbrooke’s cognitive 
examination




    X X
Health status and quality 
of life questionnaires





Assessment of adverse 
events
    (X) (X) (X) (X) (X)
(X)—As indicated/appropriate.
*Only applicable when patients are prospectively consented for the randomised controlled trial.
†Procedures required before randomisation.
‡Baseline MRI done for clinical purposes can be done from hospital admission up to 7 days after randomisation.
§Diagnostic lumbar puncture for clinical purposes done prior to randomisation.
¶Recorded prior to randomisation, daily for the first 14 days and then weekly until discharge/30 days (whichever sooner).
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memory score will be compared between groups using 
linear regression. The model will be adjusted for prespec-
ified variables which are judged to be potentially related 
to the outcome, including age and admission Glasgow 
Coma Scale Score. No interim analysis is planned, but 
there is regular monitoring by the IDSMC.
As there may be some missing primary outcome data 
due to death, inability to complete the assessment, or loss 
to follow- up, a sensitivity analysis will be carried out. All 
randomised patients will be included in this analysis.
For continuous secondary outcome variables, compar-
isons between groups will be analysed as per the primary 
outcome. The results for residual viral presence in the 
CSF at 2 weeks will be reported with a 95% CI for the 
difference in proportions between groups. Time to event 
outcomes will be analysed using Kaplan- Meier curves, 
log rank tests and Cox proportional hazards models. 
Binary secondary outcomes will be analysed using logistic 
regression.
Trial promotion and engagement
Because a previous similar study (the GACHE trial) was 
stopped early due to poor recruitment rates, we have 
put particular effort into maximising recruitment. This 
has included keeping the (NOTE) principal investiga-
tors, research nurses and the community engaged in 
the trial. The trial is being publicised regularly using the 
Encephalitis Society website and newsletter, social media, 
and patient journey articles. The Encephalitis Society 
are playing a key role in providing additional support to 
the patients and their families aside from their work for 
the trial. At the annual World Encephalitis Day we have 
engaged with clinicians, patients, families and the public 
to raise awareness of encephalitis and the trial, especially 
through social media, newspapers, radio and television. 
To promote site engagement, study days are arranged for 
research teams to attend, along with scheduled research 
nurse teleconferences to allow ideas on maximising 
recruitment and updates on trial progress to be shared. 
Research investigators are invoted to the annual Neuro-
logical Infectious Diseases course in Liverpool45 Sites are 
also kept updated through our website ( www. dexenceph. 
org. uk), and newsletters. In addition we use an innovative 
sticker chart, whereby a sticker is sent out to every site 
each time a patient is recruited anywhere in the country, 
approximately once a month (figure 2); this helps keep 
the study at the forefront of investigators minds. In addi-
tion, in case the DexEnceph study did not recrut to target 
a parralele study was set up by French colleagues, using 
the same protocol, so that data could be pooled if needed.
Trial closure
The end of the trial is defined to be the date on which 
data for all participants is frozen and data entry privileges 
are withdrawn from the trial database. The trial may be 
closed prematurely by the trial steering committee, on 
the recommendation of the IDSMC if there is sufficient 
evidence of risk to patient safety.
Pharmacovigilance
Oversight of the trial is provided by the trial steering 
committee, which meets at least annually to review trial 
progress, safety, and adverse events (AEs). The committee 
is also informed of any protocol changes by the clinical 
trial research unit.
The Medicines for Human Use (Clinical Trials) Regu-
lations 2004 (SI 2004/1031) definitions are used for AE, 
adverse reaction (AR), unexpected AR, serious AE (SAE), 
serious AR (SAR) or suspected unexpected SAR(SUSAR).
Depending on the nature of the event the reporting 
procedures below are followed:
1. SAEs occurring up to 30 days after randomisation are 
reported through an SAE Form (if serious) or in the 
30 days/discharge case record forms (CRF) if they are 
a notable event (positive PCR in CSF at second lum-
bar puncture, gastrointestinal bleed, hyperglycaemia 
requiring change in medical management, opportu-
nistic infections, unexpected/severe neuropsychiatric 
events).
2. SAEs occurring after 30 days from randomisation are 
monitored through reporting in the CRFs with safe-
ty data collected in the 26 weeks and 78 weeks CRFs if 
serious.
The research investigator at each study site (or desig-
nated other) assesses all AEs for seriousness, causality 
Figure 2 DexEnceph sticker chart.
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and severity. The chief investigator (or designated other) 
assesses all adverse drug reactions for expectedness from 
known side effects of the use of dexamethasone.46 All 
serious ARs, AEs and SUSARs occurring up to 30 days 
from randomisation (apart from death unless the investi-
gator suspects causality) require reporting to the clinical 
trials unit, within 24 hours of the site becoming aware of 
the event. In the case of death of a patient causality will be 
assessed by the trial steering committee.
The clinical trials unit will notify the Medicines and 
Healthcare products Regulatory Agency and main 
research ethics committee of all SUSARs that occur 
during the study according to the following timelines; 
fatal and life- threatening within 7 days of notification and 
non- life- threatening within 15 days. All investigators are 
informed of all SUSARs occurring throughout the study.
SAEs occurring after 30 days from randomisation are 
monitored by the clinical trials unit via the 26 weeks and 
78 weeks CRFs. These CRFs need to be received at the 
clinical trials research unit by 4 weeks after the 26 and 6 
weeks after 78 weeks time points.
Safety data are provided to the IDSMC, who are respon-
sible for safeguarding the interests of trial participants 
and assessing the safety of the interventions during the 
trial; the IDSMC ensures action is taken as needed should 
they become aware of trends in reported AEs that raise 
safety concerns.
Trial funding and financial arrangements
Contractual agreements are in place between the sponsor 
and collaborating centres that describe financial arrange-
ments. Trial participants are not paid to participate in the 
trial but are paid travel expenses for the follow- up visits. 
Payments to sites are made per site initiation but the 
bulk of payments are made per patient recruitment. Sites 
receive payment for: clinical time oversight, research 
nurse time, administrative support, MRI scanning and 
pharmacy oversight.
Patient and public involvement
The Encephalitis Society was consulted and provided 
advice on the design of the trial and the difficulties partic-
ipants and their families encounter. The chief investigator 
of the DexEnceph study is the President of the Enceph-
alitis Society. The chief executive of The Encephalitis 
Society is a coapplicant on the grant application and a 
coauthor on this paper.
The Encephalitis Society has also provided patient 
representatives at our trial steering committee and 
assisted in the production and dissemination of trial 
promotional materials.
The Encephalitis Society will support publication and 
dissemination of the trial findings among lay, therapeutic 
and health professionals through the use of web materials, 
newsletters and guides as well as at conferences and semi-
nars. All patients and their family/carers will be acknowl-
edged in any outputs from the trial. We also work with 
The Encephalitis Society on a programme of teaching 
events and produce guides for healthcare professionals 
and lay people.
In instances where trial participants and their families 
have ongoing difficulties the central study team seek help 
for them through the Encephalitis Society and appro-
priate specialists for further assistance.
Ethics and dissemination
The trial falls within the remit of the EU Directive 
2001/20/EC, transposed into UK law as the UK Statutory 
Instrument 2004 No 1031: Medicines for Human Use 
(Clinical Trials) Regulations 2004 as amended. This trial 
is registered with the Medicines and Healthcare products 
Regulatory Agency (MHRA) and granted Clinical Trial 
Authorisation (CTA). The EUDRACT number for CTA 
reference is 2015-001609-16. Ethical approval has been 
obtained from a multicentre research ethics committee 
familiar with the principals of the Mental Capacity Act 
2005 guidance for sites in England and Wales and the 
Adults with Incapacity Act 2008 for sites in Scotland as the 
principals are relevant to a clinical trial of investigational 
medicinal products (CTIMP). Clinical Research Gover-
nance approval was given through the Sponsor, The 
University of Liverpool. The trial protocol was approved 
by a National Research Ethics Service Committee refer-
ence is 2015-001609-16 (Attained 31 March 2016) and 
underwent independent review at the Research and 
Development offices at participating sites. This study 
abides by the principles of the World Medical Association 
Declaration of Helsinki (1964) and Tokyo (1975), Venice 
(1983), Hong Kong (1989) and South Africa (1996). 
Due to the nature of this trial it also abides by the Medi-
cine for Human Use (Clinical Trials) regulations 2004 
(S.I.2004:1031) and all following amendments which are 
incorporated into UK law.
Informed consent process
In obtaining and documenting informed consent, the 
investigators adhere to National Institute for Health 
Research (NIHR) Good Clinical Practice guidelines and 
the ethical principles derived from the Declaration of 
Helsinki. Staff delegated by the principal investigator 
and appropriately trained with experience in obtaining 
informed consent, discuss the objectives, risks and incon-
veniences of the trial and the conditions under which it 
is to be conducted with the patient or if the patient lacks 
capacity with a legal or professional representative. Trial 
information documents and points of contact for further 
information are provided and the potential participants 
are given adequate time to consider their decision(online 
supplemental file 2).
As this is a CTIMP, the clinical trial regulations for 
incapacitated adults are followed (Medicines for Human 
Use Clinical Trial Regulations 2004 and amendments). 
When a legal representative has given consent for a 
patient to participate in the trial and the patient subse-
quently regains capacity, the research team will provide 
the patient information sheet and request consent from 
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the participant. Patients are allowed to withdraw from the 
study at any point and may request withdrawal of their 
data collected until this point. Prospective consent can 
also be obtained prior to a positive PCR result so partici-
pants may have adequate time for contemplation.
As suspected encephalitis is a medical emergency, a 
deferred consent process is used for the collection and 
retention of some samples as part of routine clinical 
management. Using emergency deferred consent for 
samples involves taking additional samples of blood and 
CSF only if the procedure is being performed for clinical 
care. If deferred consent has been used, written consent 
is requested from either the patient or a legal represen-
tative as soon as is possible and appropriate, with samples 
discarded if this is declined. This approach is based on 
discussions with patients and the public through the 
Encephalitis Society.
Data capture methods
Data are stored securely in line with the Data Protection 
Act 1998. The randomisation system, data capture form 
and CRF have been designed to optimally protect partic-
ipant information and to maintain confidentiality. Trial 
data are captured at local sites using paper CRFs. These 
are then sent into the clinical trials research unit for data 
entry into the study- specific database. Completed CRFs 
are returned to clinical trial research centre within 7 days 
of completion. A copy of the CRF sent over to the clinical 
trials research unit is retained at site. CRFs and consent 
forms are stored separately and securely at all times in 
dedicated areas of the clinical trials research unit.
CRFs are checked for data quality by the clinical trials 
research unit in Liverpool responsible for ensuring data 
collection and storage.
Patients’ anonymised and labelled neuroimaging data 
are put on to discs at site and sent to the clinical trials 
research unit; the images can also be transferred via the 
Image Exchange Portal in an encrypted manner. The 
final dataset will be solely accessible to the central study 
team at the University of Liverpool for analysis and write 
up.
Dissemination
The results of the DexEnceph trial will be published in 
a high impact journal in a timely manner to present the 
findings to front- line clinicians. They will be presented 
at the annual conference organised by the Encephalitis 
Society and at other meetings. Authorship of the final 
papers will be determined in accordance with the interna-
tional committee of medical journal editors’ guidelines. 
The investigators will be involved in the preparation and 
drafting of the manuscripts. There is no intended use of 
professional writers.
DISCUSSION
This protocol describes the design of a randomised 
controlled trial to examine the role of dexamethasone in 
the management of patients with HSV encephalitis. HSV 
encephalitis is a rare sporadic acute disease, and the trial 
has been designed to take this challenge into account, 
along with the practicalities of running the trial in a UK 
National Health Service setting. In particular lessons were 
learnt from a previous similar European study, the GACHE 
trial, which was stopped early because of recruitment 
difficulties. Recruitment to the GACHE trial necessitated 
patients had focal neurological signs of no longer than 
5 days prior to admission, while DexEnceph has less strin-
gent criteria and reflects the diverse ways in which HSV 
encephalitis may present. DexEnceph has been designed 
to be both practical and pragmatic, in that patients must 
be recruited within 7 days of the PCR result becoming 
available. This allows for occasions where it may take 
longer to get the PCR performed, and also allows time for 
patients admitted to district general hospitals, which may 
not be study centres, to be transferred to larger hospitals 
which are. DexEnceph also has the advantage in that its 
recruitment projections were based on preliminary data 
garnered from the ENCEPH- UK NIHR programme ( 
www. encephuk. org) and from a multicentre cohort study 
of encephalitis in England, run by the Health Protection 
Agency (fore- runner to the Health Protection Agency).9 
These two studies provided direct information on the 
number of HSV encephalitis patients presenting to UK 
hospitals. The GACHE study was a double- blind placebo 
controlled study. Our choice of an open- label observer- 
blind study, avoided the logistic challenges of ensuring 
blinded study drug was available across the large number 
of centres, which might each see only one to two patients 
per year. We are confident our robust monitoring and 
trial promotion ensures the majority of eligible patients 
are recruited. NMDA receptor antibody encephalitis 
(which is treated with corticosteroids and other immuno-
modulatory therapies) is being recognised increasingly as 
a late complication of HSV encephalitis.47 48 DexEnceph 
may also be able examine whether corticosteroids reduce 
the incidence of this complication. If there is demon-
strable efficacy of corticosteroid in improving neuro-
psychological, imaging and quality of life outcomes, 
without compromising patient safety the results will be 
far reaching.
Collaboration with France
Because we recognised from the start that there may be 
difficulties keeping to recruitment targets in the DexEn-
ceph study, we worked with colleagues in France to 
develop a parallel French study (DexEnceph- France). 
This follows the UK DexEnceph protocol as closely as 
possible, while being pragmatic about the constraints of a 
different country’s healthcare system. The French trial is 
based in 10 hospitals with the lead centre being Grenoble 
Alpes University Hospital and the aim of recruiting 30 
patients.
The intention is for the two trials to be analysed sepa-
rately, with the option of also combining them into an 









pen: first published as 10.1136/bm




9Whitfield T, et al. BMJ Open 2021;11:e041808. doi:10.1136/bmjopen-2020-041808
Open access
overall analysis which will give additional power to detect 
a treatment effect.
Trial status
The trial was opened in the UK in August 2016. By June 
2019 it was running at 45 NHS trusts, and
by Feburary 2020 71 patients had been randomised. 
However, in March 2020 recruitment to the trial was 
paused, along with most other NIHR- funded studies, 
because of the Covid-19 pandemic. However ongoing 
assessment was completed for patients in the study, and 
the primary outcome was not missed for a single such 
patient. Conducting such assessments despite social 
distancing requirements required some ingenuity on 
the part of the neuropsychology team. Recuitment to 
the study reopened in June 2020 (one of the first non- 
Covid-19 studies to do so) and by June 2021 had recruited 
82 (91%) of the target 90 patients. The progress of the 
trial through the pandemic is a testament to the committ-
ment of the research teams around the country, as well 
as the patients and their families. The trial is currently 
expected to complete recruitment in January 2022, 
and to complete followu up for the primary outcome 6 
months later. The research team have used the lessons 
learnt in conducting a randomised controlled acute 
treatment trial of this rare disease to apply succesfully for 
funding to study the role of intravenous immunoglobulin 
(IVIG) in autoimmune encephalitis.If you are interested 
in seeing whether your hospital could become involved 
in the Enceph- IG study please visit www. liverpool. ac. uk/ 
encephig, or email:  encephig@ liverpool. ac. uk
 
Author affiliations
1Department of Clinical Infection, Medical Microbiology and Immunology, University 
of Liverpool, Liverpool, UK
2Clinical Trials Research Centre, University of Liverpool, Liverpool, UK
3PLEASE REMOVE THIS ADDRESS ENTRY, X, X, X
4Tropical and Infectious Diseases Unit, Liverpool University Hospitals Foundation 
Trust, Liverpool, UK
5Neurology Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
6Pharmacy Department, Liverpool University Hospitals NHS Foundation Trust, 
Liverpool, UK
7Department of Biostatistics, Faculty of Health and Life Sciences, University of 
Liverpool, Liverpool, UK
8Deptment of Clinical Neuropsychology, The Walton Centre NHS Foundation Trust, 
Liverpool, UK
9Neuroradiology Department, The Walton Centre NHS Foundation Trust, Liverpool, 
UK
10South London Specialist Virology Centre, King's College Hospital NHS Foundation 
Trust, London, UK
11Division of Neuroscience & Experimental Psychology, University of Manchester, 
Manchester, UK
12The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, 
UK
13The Encephalitis Society, Malton, North Yorkshire, UK
14Service des Maladies Infectieuses et Tropicales, CHU Grenoble Alpes, Grenoble, 
Rhône- Alpes, France
15Department of Neurology, Alder Hey Children’s NHS Foundation Trust, Liverpool, 
UK
16REMOVE THI ADDRESS, XXXXX, XXX, XXX
17Infectious Diseases Department, University of Grenoble, Grenoble, UK
18Department of Neurology, Walton Centre NHS Foundation Trust, Liverpool, UK
19National Institute for Health Research Health Protection Research Unit in Emerging 
and Zoonotic Infections, Institute of Infection Ecology and Veterinary Sciences, 
University of Liverpool, Liverpool, UK
Twitter Sylviane Defres @sdefres
Contributors All authors were consulted and inputted into the article, below 
lists the particular role within DexEnceph. TW: clinical research fellow, CF: clinical 
research fellow, KD: trials manager, SD: contributor to trial design and running, MG: 
Clinical and laboratory biomarkers lead, CH: neuropsychology researcher, RT: trial 
pharmacist, GB: trial statistician, AR- H: trial statistician, PM: neuropsychology lead, 
KDas: neuroimaging lead, MZ: virology, LP: neuroimaging, SK: neuroimaging, NR: 
neuroimaging, AE: encephalitis society chief executive advisor, ST: study coordinator 
France, RK: clinical lead brain infections UK, JPS: principal investigator France, TS: 
chief investigator responsible for the trial.
Funding This trial is funded by the NIHR Efficacy and Mechanism Evaluation 
Programme for the Department of Health reference 12/205/28.
Competing interests TS is supported by the National Institute for Health Research 
(NIHR) Health Protection Research Unit in Emerging and Zoonotic Infections (Grant 
No. IS- HPU-1112-10117), NIHR Global Health Research Group on Brain Infections 
(No. 17/63/110), and the European Union's Horizon 2020 research and innovation 
program ZikaPLAN (Preparedness Latin America Network), grant agreement No. 
734584.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iD
Thomas Whitfield http:// orcid. org/ 0000- 0002- 4016- 2712
REFERENCES
 1 Davison KL, Crowcroft NS, Ramsay ME, et al. Viral encephalitis 
in England, 1989-1998: what did we miss? Emerg Infect Dis 
2003;9:234–40.
 2 Whitley RJ. Herpes simplex encephalitis: adolescents and adults. 
Antiviral Res 2006;71:141–8.
 3 Mailles A, Stahl J- P, Steering Committee and Investigators Group. 
Infectious encephalitis in France in 2007: a national prospective 
study. Clin Infect Dis 2009;49:1838–47.
 4 Granerod J, Cousens S, Davies NWS, et al. New estimates 
of incidence of encephalitis in England. Emerg Infect Dis 
2013;19:1455–62.
 5 Solomon T, Hart IJ, Beeching NJ, et al. Viral encephalitis : a clinician ’ 
s guide 2007:288–305.
 6 Easton A. Encephalitis: raising awareness and collaborating in 
research. Lancet Neurol 2016;15:353.
 7 McGrath N, Anderson NE, Croxson MC, et al. Herpes simplex 
encephalitis treated with acyclovir: diagnosis and long term outcome. 
J Neurol Neurosurg Psychiatry 1997;63:321–6.
 8 Jouan Y, Grammatico- Guillon L, Espitalier F, et al. Long- Term 
outcome of severe herpes simplex encephalitis: a population- based 
observational study. Crit Care 2015;19:345.
 9 Granerod J, Ambrose HE, Davies NW, et al. Causes of encephalitis 
and differences in their clinical presentations in England: a 
multicentre, population- based prospective study. Lancet Infect Dis 
2010;10:835–44.









pen: first published as 10.1136/bm




10 Whitfield T, et al. BMJ Open 2021;11:e041808. doi:10.1136/bmjopen-2020-041808
Open access 
 10 Raschilas F, Wolff M, Delatour F, et al. Outcome of and prognostic 
factors for herpes simplex encephalitis in adult patients: results of a 
multicenter study. Clin Infect Dis 2002;35:254–60.
 11 Egdell R, Egdell D, Solomon T. Herpes simplex virus encephalitis. 
BMJ 2012;344:e3630
 12 Utley TF, Ogden JA, Gibb A, et al. The long- term neuropsychological 
outcome of herpes simplex encephalitis in a series of unselected 
survivors. Neuropsychiatry Neuropsychol Behav Neurol 
1997;10:180–9 http://www. ncbi. nlm. nih. gov/ pubmed/ 9297711
 13 Frisch S, Thiel F, Marschhauser A, et al. Identifying neural 
correlates of memory and language disturbances in herpes simplex 
encephalitis: a voxel- based morphometry (VBM) study. J Neurol 
2015;262:563–9.
 14 Pewter SM, Williams WH, Haslam C, et al. Neuropsychological and 
psychiatric profiles in acute encephalitis in adults. Neuropsychol 
Rehabil 2007;17:478–505.
 15 Hokkanen L, Poutiainen E, Valanne L. Cognitive impairment after 
acute encephalitis: comparison of herpes simplex and other 
aetiologies. Neurosurgery, and Psychiatry 1994;1996:478–84.
 16 Cooper J, Kierans C, Defres S, et al. Care beyond the hospital ward: 
understanding the socio- medical trajectory of herpes simplex virus 
encephalitis. BMC Health Serv Res 2017;17:1–11.
 17 Cooper J, Kierans C, Defres S, et al. Diagnostic pathways as social 
and participatory practices: the case of herpes simplex encephalitis. 
PLoS One 2016;11:1–15.
 18 Aurelius E, Andersson B, Forsgren M, et al. Cytokines and other 
markers of intrathecal immune response in patients with herpes 
simplex encephalitis. J Infect Dis 1994;170:678–81.
 19 Sköldenberg B, Aurelius E, Hjalmarsson A, et al. Incidence and 
pathogenesis of clinical relapse after herpes simplex encephalitis in 
adults. J Neurol 2006;253:163–70.
 20 Michael BD, Griffiths MJ, Granerod J, et al. Characteristic cytokine 
and chemokine profiles in encephalitis of infectious, immune- 
mediated, and unknown aetiology. PLoS One 2016;11:e0146288.
 21 Wnęk M, Ressel L, Ricci E, et al. Herpes simplex encephalitis is 
linked with selective mitochondrial damage; a post- mortem and in 
vitro study. Acta Neuropathol 2016;132:433–51.
 22 Rösler A, Pohl M, Braune HJ, et al. Time course of chemokines in 
the cerebrospinal fluid and serum during herpes simplex type 1 
encephalitis. J Neurol Sci 1998;157:82–9.
 23 Kamei S, Taira N, Ishihara M, et al. Prognostic value of cerebrospinal 
fluid cytokine changes in herpes simplex virus encephalitis. Cytokine 
2009;46:187–93.
 24 Taira N, Kamei S, Morita A, et al. Predictors of a prolonged clinical 
course in adult patients with herpes simplex virus encephalitis. Intern 
Med 2009;48:89–94.
 25 Kapur N, Barker S, Burrows EH, et al. Herpes simplex encephalitis: 
long term magnetic resonance imaging and neuropsychological 
profile. J Neurol Neurosurg Psychiatry 1994;57:1334–42.
 26 Bale JF, Du Pasquier R. Relapse in herpes simplex virus encephalitis. 
Neurology 2015;85:1730–1.
 27 Meyding- Lamadé UK, Oberlinner C, Rau PR, et al. Experimental 
herpes simplex virus encephalitis: a combination therapy of acyclovir 
and glucocorticoids reduces long- term magnetic resonance imaging 
abnormalities. J Neurovirol 2003;9:118–25.
 28 Sellner J, Dvorak F, Zhou Y, et al. Acute and long- term alteration of 
chemokine mRNA expression after anti- viral and anti- inflammatory 
treatment in herpes simplex virus encephalitis. Neurosci Lett 
2005;374:197–202.
 29 Meyding- Lamadé U, Seyfer S, Haas J, et al. Experimental 
herpes simplex virus encephalitis: inhibition of the expression of 
inducible nitric oxide synthase in mouse brain tissue. Neurosci Lett 
2002;318:21–4.
 30 Upton AR, Barwick D, Foster J. Dexamethasone treatment in herpes- 
simplex encephalitis. Lancet 1971;297:290–1.
 31 Habel AH, Brown JK. Dexamethasone in herpes- simplex 
encephalitis. The Lancet 1972;299:695.
 32 Defres S, Keller SS, Das K, et al. A feasibility study of quantifying 
longitudinal brain changes in herpes simplex virus (HSV) encephalitis 
using magnetic resonance imaging (MRI) and stereology. PLoS One 
2017;12:1–15.
 33 de Gans J, van de Beek D, European Dexamethasone in Adulthood 
Bacterial Meningitis Study Investigators. Dexamethasone in adults 
with bacterial meningitis. N Engl J Med 2002;347:1549–56.
 34 Kamei S, Sekizawa T, Shiota H, et al. Evaluation of combination 
therapy using aciclovir and corticosteroid in adult patients with 
herpes simplex virus encephalitis. J Neurol Neurosurg Psychiatry 
2005;76:1544–9.
 35 Musallam B, Matoth I, Wolf DG, et al. Steroids for deteriorating 
herpes simplex virus encephalitis. Pediatr Neurol 2007;37:229–32.
 36 Maraş Genç H, Uyur Yalçın E, Sayan M, et al. Clinical outcomes in 
children with herpes simplex encephalitis receiving steroid therapy. J 
Clin Virol 2016;80:87–92.
 37 Nakano A, Yamasaki R, Miyazaki S, et al. Beneficial effect of steroid 
pulse therapy on acute viral encephalitis. Eur Neurol 2003;50:225–9.
 38 Lizarraga KJ, Alexandre LC, Ramos- Estebanez C, et al. Are steroids 
a beneficial adjunctive therapy in the immunosuppressed patient with 
herpes simplex virus encephalitis? Case Rep Neurol 2013;5:52–5.
 39 Mesker AJ, Bon GG, de Gans J, et al. Case report: a pregnant 
woman with herpes simplex encephalitis successfully treated with 
dexamethasone. Eur J Obstet Gynecol Reprod Biol 2011;154:231–2.
 40 Martinez- Torres F, Menon S, Pritsch M, et al. Protocol for German 
trial of Acyclovir and corticosteroids in Herpes- simplex- virus- 
encephalitis (GACHE): a multicenter, multinational, randomized, 
double- blind, placebo- controlled German, Austrian and Dutch trial 
[ISRCTN45122933]. BMC Neurol 2008;8:40.
 41 Hro A, Mann H, Dickersin K. Research and Reporting Methods 
Annals of Internal Medicine SPIRIT 2013 Statement : Defining 
Standard Protocol Items for Clinical Trials. Ann Intern Med 
2015;1:200–7.
 42 The medicines for human use (clinical trials) regulations, 2004. 
Available: http://www. legislation. gov. uk/ uksi/ 2004/ 1031/ schedule/ 1/ 
made [Accessed 19 Jun 2019].
 43 Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus 
acyclovir therapy in herpes simplex encephalitis. N Engl J Med 
1986;314:144–9.
 44 Sköldenberg B, Alestig K, Burman L. Acyclovir versus vidarabine in 
herpes simplex encephalitis. Lancet 1984;324:707–11.
 45 Kesavelu D. Liverpool neurological infectious diseases course. BMJ 
2009;339:b3916 https://www. bmj. com/ content/ 339/ bmj. b3916 
doi:10.1136/bmj.b3916
 46 Spc. dexamethasone SPC 2014:1–4.
 47 Gilbert GJ, Leypoldt F, Dalmau J. Herpes simplex virus-1 encephalitis 
can trigger anti- NMDA receptor encephalitis: case report. Neurology 
2014;82:2041
 48 Leypoldt F, Titulaer MJ, Aguilar E, et al. Herpes simplex virus-1 
encephalitis can trigger anti- NMDA receptor encephalitis: case 
report. Neurology 2013;81:1637–9.









pen: first published as 10.1136/bm
jopen-2020-041808 on 22 July 2021. D
ow
nloaded from
 
